APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.

Selected research

Market Structure

Global Human Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025199 pages

Choose your research edition.

Industry ResearchHuman Vaccine Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Human Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.

In China, Human Vaccine key players include CNBG, Kangtai, ChengDa Bio, etc. Global top three manufacturers hold a share about 65%.

East China is the largest market, with a share about 25%, followed by South China, and North China, both have a share about 40 percent.

Read the full market overview

In terms of product, Hepatitis B is the largest segment, with a share nearly 15%. And in terms of application, the largest application is Children, followed by Adults.

This report provides an overview of the global Human Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Vaccine Segment by Company

CNBG

Changsheng Life

Zhifei

ChengDa Bio

Kangtai

SINOVAC BIOTECH

Hissen

Walvax Biotechnology

GSK

SANOFI

Rong An

NuoCheng Bio

Hualan Bio

Tiantan biological

Changchun Baike

Adimmune

Zhongyianke Biotech

Bharat Biotech

Bavarian Nordic

Sanofi-Pasteur

Indian Immunologicals

KANGH

Henan Grand Biopharma

ZhongKe Biopharm

Zhuoyi Biological

Human Vaccine Segment by Type

Varicella

Influenza

Polio

Hepatitis A

Rabies

BCG

Hepatitis B

Pertussis, Diphtheria, Tetanus

Pneumococcal

Rota vaccine

Human Vaccine Segment by Application

Adults

Children

Human Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Vaccine Industry Trends Table 2. Human Vaccine Industry Drivers Table 3. Human Vaccine Industry Opportunities and Challenges Table 4. Human Vaccine Industry Restraints Table 5. Global Human Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Vaccine Sales by Manufacturers (M Doses) & (2021-2026) Table 8. Global Human Vaccine Sales Market Share by Manufacturers Table 9. Global Human Vaccine Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Human Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Vaccine Manufacturers, Product Type & Application Table 13. Global Human Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Varicella Table 17. Major Manufacturers of Influenza Table 18. Major Manufacturers of Polio Table 19. Major Manufacturers of Hepatitis A Table 20. Major Manufacturers of Rabies Table 21. Major Manufacturers of BCG Table 22. Major Manufacturers of Hepatitis B Table 23. Major Manufacturers of Pertussis, Diphtheria, Tetanus Table 24. Major Manufacturers of Pneumococcal Table 25. Major Manufacturers of Rota vaccine Table 26. Global Human Vaccine Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 27. Global Human Vaccine Sales by Type (2021-2026) & (M Doses) Table 28. Global Human Vaccine Sales by Type (2027-2032) & (M Doses) Table 29. Global Human Vaccine Sales Market Share by Type (2021-2026) Table 30. Global Human Vaccine Sales Market Share by Type (2027-2032) Table 31. Global Human Vaccine Revenue by Type 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Human Vaccine Revenue by Type (2021-2026) & (M Doses) Table 33. Global Human Vaccine Revenue by Type (2027-2032) & (M Doses) Table 34. Global Human Vaccine Revenue Market Share by Type (2021-2026) Table 35. Global Human Vaccine Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Adults Table 37. Major Manufacturers of Children Table 38. Global Human Vaccine Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 39. Global Human Vaccine Sales by Application (2021-2026) & (M Doses) Table 40. Global Human Vaccine Sales by Application (2027-2032) & (M Doses) Table 41. Global Human Vaccine Sales Market Share by Application (2021-2026) Table 42. Global Human Vaccine Sales Market Share by Application (2027-2032) Table 43. Global Human Vaccine Revenue by Application 2021 VS 2025 VS 2032 (M Doses) Table 44. Global Human Vaccine Revenue by Application (2021-2026) & (M Doses) Table 45. Global Human Vaccine Revenue by Application (2027-2032) & (M Doses) Table 46. Global Human Vaccine Revenue Market Share by Application (2021-2026) Table 47. Global Human Vaccine Revenue Market Share by Application (2027-2032) Table 48. Global Human Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 49. Global Human Vaccine Sales by Region (2021-2026) & (M Doses) Table 50. Global Human Vaccine Sales Market Share by Region (2021-2026) Table 51. Global Human Vaccine Sales Forecasted by Region (2027-2032) & (M Doses) Table 52. Global Human Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 53. North America Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. North America Human Vaccine Sales by Country (2021-2026) & (M Doses) Table 55. North America Human Vaccine Sales by Country (2027-2032) & (M Doses) Table 56. Europe Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 57. Europe Human Vaccine Sales by Country (2021-2026) & (M Doses) Table 58. Europe Human Vaccine Sales by Country (2027-2032) & (M Doses) Table 59. Asia Pacific Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 60. Asia Pacific Human Vaccine Sales by Country (2021-2026) & (M Doses) Table 61. Asia Pacific Human Vaccine Sales by Country (2027-2032) & (M Doses) Table 62. South America, Middle East and Africa Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 63. South America, Middle East and Africa Human Vaccine Sales by Country (2021-2026) & (M Doses) Table 64. South America, Middle East and Africa Human Vaccine Sales by Country (2027-2032) & (M Doses) Table 65. Global Human Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Human Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 67. Global Human Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 68. Global Human Vaccine Revenue Market Share by Region (2021-2026) Table 69. Global Human Vaccine Revenue Market Share by Region (2027-2032) Table 70. CNBG Company Information Table 71. CNBG Business Overview Table 72. CNBG Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. CNBG Human Vaccine Product Portfolio Table 74. CNBG Recent Development Table 75. Changsheng Life Company Information Table 76. Changsheng Life Business Overview Table 77. Changsheng Life Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Changsheng Life Human Vaccine Product Portfolio Table 79. Changsheng Life Recent Development Table 80. Zhifei Company Information Table 81. Zhifei Business Overview Table 82. Zhifei Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Zhifei Human Vaccine Product Portfolio Table 84. Zhifei Recent Development Table 85. ChengDa Bio Company Information Table 86. ChengDa Bio Business Overview Table 87. ChengDa Bio Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. ChengDa Bio Human Vaccine Product Portfolio Table 89. ChengDa Bio Recent Development Table 90. Kangtai Company Information Table 91. Kangtai Business Overview Table 92. Kangtai Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Kangtai Human Vaccine Product Portfolio Table 94. Kangtai Recent Development Table 95. SINOVAC BIOTECH Company Information Table 96. SINOVAC BIOTECH Business Overview Table 97. SINOVAC BIOTECH Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. SINOVAC BIOTECH Human Vaccine Product Portfolio Table 99. SINOVAC BIOTECH Recent Development Table 100. Hissen Company Information Table 101. Hissen Business Overview Table 102. Hissen Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Hissen Human Vaccine Product Portfolio Table 104. Hissen Recent Development Table 105. Walvax Biotechnology Company Information Table 106. Walvax Biotechnology Business Overview Table 107. Walvax Biotechnology Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Walvax Biotechnology Human Vaccine Product Portfolio Table 109. Walvax Biotechnology Recent Development Table 110. GSK Company Information Table 111. GSK Business Overview Table 112. GSK Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. GSK Human Vaccine Product Portfolio Table 114. GSK Recent Development Table 115. SANOFI Company Information Table 116. SANOFI Business Overview Table 117. SANOFI Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. SANOFI Human Vaccine Product Portfolio Table 119. SANOFI Recent Development Table 120. Rong An Company Information Table 121. Rong An Business Overview Table 122. Rong An Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Rong An Human Vaccine Product Portfolio Table 124. Rong An Recent Development Table 125. NuoCheng Bio Company Information Table 126. NuoCheng Bio Business Overview Table 127. NuoCheng Bio Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. NuoCheng Bio Human Vaccine Product Portfolio Table 129. NuoCheng Bio Recent Development Table 130. Hualan Bio Company Information Table 131. Hualan Bio Business Overview Table 132. Hualan Bio Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Hualan Bio Human Vaccine Product Portfolio Table 134. Hualan Bio Recent Development Table 135. Tiantan biological Company Information Table 136. Tiantan biological Business Overview Table 137. Tiantan biological Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Tiantan biological Human Vaccine Product Portfolio Table 139. Tiantan biological Recent Development Table 140. Changchun Baike Company Information Table 141. Changchun Baike Business Overview Table 142. Changchun Baike Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Changchun Baike Human Vaccine Product Portfolio Table 144. Changchun Baike Recent Development Table 145. Adimmune Company Information Table 146. Adimmune Business Overview Table 147. Adimmune Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Adimmune Human Vaccine Product Portfolio Table 149. Adimmune Recent Development Table 150. Zhongyianke Biotech Company Information Table 151. Zhongyianke Biotech Business Overview Table 152. Zhongyianke Biotech Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Zhongyianke Biotech Human Vaccine Product Portfolio Table 154. Zhongyianke Biotech Recent Development Table 155. Bharat Biotech Company Information Table 156. Bharat Biotech Business Overview Table 157. Bharat Biotech Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Bharat Biotech Human Vaccine Product Portfolio Table 159. Bharat Biotech Recent Development Table 160. Bavarian Nordic Company Information Table 161. Bavarian Nordic Business Overview Table 162. Bavarian Nordic Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Bavarian Nordic Human Vaccine Product Portfolio Table 164. Bavarian Nordic Recent Development Table 165. Sanofi-Pasteur Company Information Table 166. Sanofi-Pasteur Business Overview Table 167. Sanofi-Pasteur Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Sanofi-Pasteur Human Vaccine Product Portfolio Table 169. Sanofi-Pasteur Recent Development Table 170. Indian Immunologicals Company Information Table 171. Indian Immunologicals Business Overview Table 172. Indian Immunologicals Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Indian Immunologicals Human Vaccine Product Portfolio Table 174. Indian Immunologicals Recent Development Table 175. KANGH Company Information Table 176. KANGH Business Overview Table 177. KANGH Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. KANGH Human Vaccine Product Portfolio Table 179. KANGH Recent Development Table 180. Henan Grand Biopharma Company Information Table 181. Henan Grand Biopharma Business Overview Table 182. Henan Grand Biopharma Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Henan Grand Biopharma Human Vaccine Product Portfolio Table 184. Henan Grand Biopharma Recent Development Table 185. ZhongKe Biopharm Company Information Table 186. ZhongKe Biopharm Business Overview Table 187. ZhongKe Biopharm Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. ZhongKe Biopharm Human Vaccine Product Portfolio Table 189. ZhongKe Biopharm Recent Development Table 190. Zhuoyi Biological Company Information Table 191. Zhuoyi Biological Business Overview Table 192. Zhuoyi Biological Human Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 193. Zhuoyi Biological Human Vaccine Product Portfolio Table 194. Zhuoyi Biological Recent Development Table 195. Key Raw Materials Table 196. Raw Materials Key Suppliers Table 197. Human Vaccine Distributors List Table 198. Human Vaccine Customers List Table 199. Research Programs/Design for This Report Table 200. Authors List of This Report Table 201. Secondary Sources Table 202. Primary Sources List of Figures Figure 1. Human Vaccine Product Image Figure 2. Global Human Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Human Vaccine Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Human Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Varicella Image Figure 9. Influenza Image Figure 10. Polio Image Figure 11. Hepatitis A Image Figure 12. Rabies Image Figure 13. BCG Image Figure 14. Hepatitis B Image Figure 15. Pertussis, Diphtheria, Tetanus Image Figure 16. Pneumococcal Image Figure 17. Rota vaccine Image Figure 18. Global Human Vaccine Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 19. Global Human Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human Vaccine Sales Market Share by Type (2021-2032) Figure 21. Global Human Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 22. Global Human Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Human Vaccine Revenue Market Share by Type (2021-2032) Figure 24. Adults Image Figure 25. Children Image Figure 26. Global Human Vaccine Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 27. Global Human Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global Human Vaccine Sales Market Share by Application (2021-2032) Figure 29. Global Human Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 30. Global Human Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global Human Vaccine Revenue Market Share by Application (2021-2032) Figure 32. North America Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 33. North America Human Vaccine Sales Market Share by Country (2021-2032) Figure 34. U.S. Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 35. Canada Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 36. Mexico Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 37. Europe Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 38. Europe Human Vaccine Sales Market Share by Country (2021-2032) Figure 39. Germany Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 40. France Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 41. U.K. Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 42. Italy Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 43. Netherlands Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 44. Asia Pacific Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 45. Asia Pacific Human Vaccine Sales Market Share by Country (2021-2032) Figure 46. China Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 47. Japan Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 48. South Korea Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 49. Southeast Asia Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 50. India Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 51. Australia Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 52. South America, Middle East and Africa Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 53. South America, Middle East and Africa Human Vaccine Sales Market Share by Country (2021-2032) Figure 54. Brazil Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 55. South Africa Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 56. Saudi Arabia Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 57. Turkey Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 58. Argentina Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 59. UAE Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 60. Egypt Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 61. Chile Human Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 62. Global Human Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global Human Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America Human Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. North America Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe Human Vaccine Revenue (2021-2032) & (US$ Million) Figure 67. Europe Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific Human Vaccine Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa Human Vaccine Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. Human Vaccine Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Human Vaccine Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella
  • Influenza
  • Polio
  • Hepatitis A
  • Rabies
  • BCG
  • Hepatitis B
  • Pertussis, Diphtheria, Tetanus
  • Pneumococcal
  • Rota vaccine
Applications
  • Adults
  • Children
Companies covered
  • CNBG
  • Changsheng Life
  • Zhifei
  • ChengDa Bio
  • Kangtai
  • SINOVAC BIOTECH
  • Hissen
  • Walvax Biotechnology
  • GSK
  • SANOFI
  • Rong An
  • NuoCheng Bio
  • Hualan Bio
  • Tiantan biological
  • Changchun Baike
  • Adimmune
  • Zhongyianke Biotech
  • Bharat Biotech
  • Bavarian Nordic
  • Sanofi-Pasteur
  • Indian Immunologicals
  • KANGH
  • Henan Grand Biopharma
  • ZhongKe Biopharm
  • Zhuoyi Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Vaccine Market Dynamics
  1. 2.1 Human Vaccine Industry Trends
  2. 2.2 Human Vaccine Industry Drivers
  3. 2.3 Human Vaccine Industry Opportunities and Challenges
  4. 2.4 Human Vaccine Industry Restraints
3 Human Vaccine Market by Manufacturers
  1. 3.1 Global Human Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Human Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Vaccine Tier 1, Tier 2, and Tier 3
4 Human Vaccine Market by Type
  1. 4.1 Human Vaccine Type Introduction
  2. 4.1.1 Varicella
  3. 4.1.2 Influenza
  4. 4.1.3 Polio
  5. 4.1.4 Hepatitis A
  6. 4.1.5 Rabies
  7. 4.1.6 BCG
  8. 4.1.7 Hepatitis B
  9. 4.1.8 Pertussis, Diphtheria, Tetanus
  10. 4.1.9 Pneumococcal
  11. 4.1.10 Rota vaccine
  12. 4.2 Global Human Vaccine Sales by Type
  13. 4.2.1 Global Human Vaccine Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Human Vaccine Sales by Type (2021-2032)
  15. 4.2.3 Global Human Vaccine Sales Market Share by Type (2021-2032)
  16. 4.3 Global Human Vaccine Revenue by Type
  17. 4.3.1 Global Human Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Human Vaccine Revenue by Type (2021-2032)
  19. 4.3.3 Global Human Vaccine Revenue Market Share by Type (2021-2032)
5 Human Vaccine Market by Application
  1. 5.1 Human Vaccine Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Human Vaccine Sales by Application
  5. 5.2.1 Global Human Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Human Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Human Vaccine Revenue by Application
  9. 5.3.1 Global Human Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Human Vaccine Revenue Market Share by Application (2021-2032)
6 Global Human Vaccine Sales by Region
  1. 6.1 Global Human Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Human Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Human Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Vaccine Revenue by Region
  1. 7.1 Global Human Vaccine Revenue by Region
  2. 7.1.1 Global Human Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CNBG
  2. 8.1.1 CNBG Company Information
  3. 8.1.2 CNBG Business Overview
  4. 8.1.3 CNBG Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CNBG Human Vaccine Product Portfolio
  6. 8.1.5 CNBG Recent Developments
  7. 8.2 Changsheng Life
  8. 8.2.1 Changsheng Life Company Information
  9. 8.2.2 Changsheng Life Business Overview
  10. 8.2.3 Changsheng Life Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Changsheng Life Human Vaccine Product Portfolio
  12. 8.2.5 Changsheng Life Recent Developments
  13. 8.3 Zhifei
  14. 8.3.1 Zhifei Company Information
  15. 8.3.2 Zhifei Business Overview
  16. 8.3.3 Zhifei Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zhifei Human Vaccine Product Portfolio
  18. 8.3.5 Zhifei Recent Developments
  19. 8.4 ChengDa Bio
  20. 8.4.1 ChengDa Bio Company Information
  21. 8.4.2 ChengDa Bio Business Overview
  22. 8.4.3 ChengDa Bio Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ChengDa Bio Human Vaccine Product Portfolio
  24. 8.4.5 ChengDa Bio Recent Developments
  25. 8.5 Kangtai
  26. 8.5.1 Kangtai Company Information
  27. 8.5.2 Kangtai Business Overview
  28. 8.5.3 Kangtai Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kangtai Human Vaccine Product Portfolio
  30. 8.5.5 Kangtai Recent Developments
  31. 8.6 SINOVAC BIOTECH
  32. 8.6.1 SINOVAC BIOTECH Company Information
  33. 8.6.2 SINOVAC BIOTECH Business Overview
  34. 8.6.3 SINOVAC BIOTECH Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SINOVAC BIOTECH Human Vaccine Product Portfolio
  36. 8.6.5 SINOVAC BIOTECH Recent Developments
  37. 8.7 Hissen
  38. 8.7.1 Hissen Company Information
  39. 8.7.2 Hissen Business Overview
  40. 8.7.3 Hissen Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hissen Human Vaccine Product Portfolio
  42. 8.7.5 Hissen Recent Developments
  43. 8.8 Walvax Biotechnology
  44. 8.8.1 Walvax Biotechnology Company Information
  45. 8.8.2 Walvax Biotechnology Business Overview
  46. 8.8.3 Walvax Biotechnology Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Walvax Biotechnology Human Vaccine Product Portfolio
  48. 8.8.5 Walvax Biotechnology Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GSK Human Vaccine Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 SANOFI
  56. 8.10.1 SANOFI Company Information
  57. 8.10.2 SANOFI Business Overview
  58. 8.10.3 SANOFI Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SANOFI Human Vaccine Product Portfolio
  60. 8.10.5 SANOFI Recent Developments
  61. 8.11 Rong An
  62. 8.11.1 Rong An Company Information
  63. 8.11.2 Rong An Business Overview
  64. 8.11.3 Rong An Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Rong An Human Vaccine Product Portfolio
  66. 8.11.5 Rong An Recent Developments
  67. 8.12 NuoCheng Bio
  68. 8.12.1 NuoCheng Bio Company Information
  69. 8.12.2 NuoCheng Bio Business Overview
  70. 8.12.3 NuoCheng Bio Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 NuoCheng Bio Human Vaccine Product Portfolio
  72. 8.12.5 NuoCheng Bio Recent Developments
  73. 8.13 Hualan Bio
  74. 8.13.1 Hualan Bio Company Information
  75. 8.13.2 Hualan Bio Business Overview
  76. 8.13.3 Hualan Bio Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hualan Bio Human Vaccine Product Portfolio
  78. 8.13.5 Hualan Bio Recent Developments
  79. 8.14 Tiantan biological
  80. 8.14.1 Tiantan biological Company Information
  81. 8.14.2 Tiantan biological Business Overview
  82. 8.14.3 Tiantan biological Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Tiantan biological Human Vaccine Product Portfolio
  84. 8.14.5 Tiantan biological Recent Developments
  85. 8.15 Changchun Baike
  86. 8.15.1 Changchun Baike Company Information
  87. 8.15.2 Changchun Baike Business Overview
  88. 8.15.3 Changchun Baike Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Changchun Baike Human Vaccine Product Portfolio
  90. 8.15.5 Changchun Baike Recent Developments
  91. 8.16 Adimmune
  92. 8.16.1 Adimmune Company Information
  93. 8.16.2 Adimmune Business Overview
  94. 8.16.3 Adimmune Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Adimmune Human Vaccine Product Portfolio
  96. 8.16.5 Adimmune Recent Developments
  97. 8.17 Zhongyianke Biotech
  98. 8.17.1 Zhongyianke Biotech Company Information
  99. 8.17.2 Zhongyianke Biotech Business Overview
  100. 8.17.3 Zhongyianke Biotech Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Zhongyianke Biotech Human Vaccine Product Portfolio
  102. 8.17.5 Zhongyianke Biotech Recent Developments
  103. 8.18 Bharat Biotech
  104. 8.18.1 Bharat Biotech Company Information
  105. 8.18.2 Bharat Biotech Business Overview
  106. 8.18.3 Bharat Biotech Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bharat Biotech Human Vaccine Product Portfolio
  108. 8.18.5 Bharat Biotech Recent Developments
  109. 8.19 Bavarian Nordic
  110. 8.19.1 Bavarian Nordic Company Information
  111. 8.19.2 Bavarian Nordic Business Overview
  112. 8.19.3 Bavarian Nordic Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bavarian Nordic Human Vaccine Product Portfolio
  114. 8.19.5 Bavarian Nordic Recent Developments
  115. 8.20 Sanofi-Pasteur
  116. 8.20.1 Sanofi-Pasteur Company Information
  117. 8.20.2 Sanofi-Pasteur Business Overview
  118. 8.20.3 Sanofi-Pasteur Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Sanofi-Pasteur Human Vaccine Product Portfolio
  120. 8.20.5 Sanofi-Pasteur Recent Developments
  121. 8.21 Indian Immunologicals
  122. 8.21.1 Indian Immunologicals Company Information
  123. 8.21.2 Indian Immunologicals Business Overview
  124. 8.21.3 Indian Immunologicals Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Indian Immunologicals Human Vaccine Product Portfolio
  126. 8.21.5 Indian Immunologicals Recent Developments
  127. 8.22 KANGH
  128. 8.22.1 KANGH Company Information
  129. 8.22.2 KANGH Business Overview
  130. 8.22.3 KANGH Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 KANGH Human Vaccine Product Portfolio
  132. 8.22.5 KANGH Recent Developments
  133. 8.23 Henan Grand Biopharma
  134. 8.23.1 Henan Grand Biopharma Company Information
  135. 8.23.2 Henan Grand Biopharma Business Overview
  136. 8.23.3 Henan Grand Biopharma Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Henan Grand Biopharma Human Vaccine Product Portfolio
  138. 8.23.5 Henan Grand Biopharma Recent Developments
  139. 8.24 ZhongKe Biopharm
  140. 8.24.1 ZhongKe Biopharm Company Information
  141. 8.24.2 ZhongKe Biopharm Business Overview
  142. 8.24.3 ZhongKe Biopharm Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 ZhongKe Biopharm Human Vaccine Product Portfolio
  144. 8.24.5 ZhongKe Biopharm Recent Developments
  145. 8.25 Zhuoyi Biological
  146. 8.25.1 Zhuoyi Biological Company Information
  147. 8.25.2 Zhuoyi Biological Business Overview
  148. 8.25.3 Zhuoyi Biological Human Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Zhuoyi Biological Human Vaccine Product Portfolio
  150. 8.25.5 Zhuoyi Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Vaccine Value Chain Analysis
  2. 9.1.1 Human Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Vaccine Production Mode & Process
  6. 9.2 Human Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Vaccine Distributors
  9. 9.2.3 Human Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst